{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:18:57Z","timestamp":1792725537400,"version":"4.5.0"},"reference-count":40,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      Cariprazine is a dopamine D\n                      <jats:sub>3<\/jats:sub>\n                      -preferring D\n                      <jats:sub>3<\/jats:sub>\n                      \/D\n                      <jats:sub>2<\/jats:sub>\n                      and serotonin 5-HT\n                      <jats:sub>1A<\/jats:sub>\n                      receptor partial agonist approved to treat adults with schizophrenia and manic\/mixed or depressive episodes associated with bipolar I disorder. This sequential-cohort, dose-escalation study was the first to evaluate the pharmacokinetic, safety, and tolerability profile of cariprazine and its two major active metabolites, desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR), in pediatric patients with schizophrenia or bipolar I disorder.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This phase I open-label study enrolled patients with schizophrenia (13\u201317 years of age) or bipolar I disorder (10\u201317 years of age). Patients met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for schizophrenia or bipolar I disorder and had Positive and Negative Syndrome Scale (PANSS) total scores \u226570 or Young Mania Rating Scale (YMRS) total scores \u226520. Patients were assigned to one of four treatment groups to receive 6 weeks of cariprazine treatment through slow titration to 1.5, 3, or 4.5\u2009mg\/d or fast titration to 4.5\u2009mg\/d. Pharmacokinetics, adverse events (AEs), and various safety parameters were analyzed. Efficacy was evaluated as an exploratory outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 50 participants were enrolled. Based on mean trough levels, steady state appeared to be reached within 1\u20132 weeks for cariprazine and DCAR and within 4\u20135 weeks for DDCAR. Systemic exposure of cariprazine, DCAR, and DDCAR generally increased approximately in proportion to the increases in dose from 1.5 to 4.5\u2009mg\/d. The most frequent treatment-related, treatment-emergent AEs included sedation, parkinsonism, tremor, dystonia, and blurred vision. Improvements from baseline on the PANSS and YMRS were observed throughout treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this first investigation of cariprazine in a pediatric population with schizophrenia or bipolar disorder, pharmacokinetic parameters were consistent with those observed in adults. Cariprazine appeared to be safe and tolerable in children and adolescents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2021.0139","type":"journal-article","created":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T13:08:25Z","timestamp":1666703305000},"page":"434-443","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3702-1097","authenticated-orcid":false,"given":"Todd","family":"Riccobene","sequence":"first","affiliation":[{"name":"AbbVie, Madison, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Riesenberg","sequence":"additional","affiliation":[{"name":"Atlanta Center for Medical Research, Atlanta, Georgia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul P.","family":"Yeung","sequence":"additional","affiliation":[{"name":"AbbVie, Madison, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willie R.","family":"Earley","sequence":"additional","affiliation":[{"name":"AbbVie, Madison, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene L.","family":"Hankinson","sequence":"additional","affiliation":[{"name":"AbbVie, Madison, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Publishing: Diagnostic and Statistical Manual of Mental Disorders 5th ed. Arlington VA: American Psychiatric Publishing; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.wpsyc.2012.01.006"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S301225"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.154.5.672"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09081"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S210340"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.15m09997"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15020164"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.11.041"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12238"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.000452011"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.18070824"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.03.032"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000187"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.11.098"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12852"},{"key":"e_1_3_4_18_1","unstructured":"Guy W: ECDEU Assessment Manual for Psychopharmacology. DHEW Publication No. 76\u2013338. Rockville MD: Rockville: National Institute of Mental Health; 1976."},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464200-00003"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/13651500310002986"},{"key":"e_1_3_4_21_1","first-page":"32","article-title":"Prolactin-related and metabolic adverse effects of atypical antipsychotic agents","volume":"1","author":"Henderson DC","year":"2008","unstructured":"Henderson DC, , Doraiswamy PM: Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry 69(Suppl, 1):32\u201344, 2008.","journal-title":"J Clin Psychiatry 69(Suppl"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1580"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000346"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-10-63"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S96392"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chc.2013.06.002"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2018.12.033"},{"key":"e_1_3_4_29_1","first-page":"149","article-title":"Clinical manifestations, evaluation and management of hyperprolactinemia in adolescent and young girls: A brief review","volume":"90","author":"Matalliotakis M","year":"2019","unstructured":"Matalliotakis M, , Koliarakis I, , Matalliotaki C, , Trivli A, , Hatzidaki E: Clinical manifestations, evaluation and management of hyperprolactinemia in adolescent and young girls: A brief review. Acta Biomed, 90:149\u2013157, 2019.","journal-title":"Acta Biomed"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000242240.69678.c4"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.02.008"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S95100"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30060-0"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-020-00650-4"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04994yel"},{"key":"e_1_3_4_37_1","unstructured":"Poznanski E Mokros H: Children's Depression Rating Scale\u2013Revised (CDRS-R). Los Angeles: WPS; 1996."},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-015-0623-4"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2014.11.018"},{"key":"e_1_3_4_40_1","unstructured":"Vraylar (cariprazine) [package insert]. Madison NJ: Allergan; 2019."},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.133.5.429"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2021.0139","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2021.0139","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2021.0139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:56:29Z","timestamp":1777388189000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2021.0139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1089\/cap.2021.0139"],"URL":"https:\/\/doi.org\/10.1089\/cap.2021.0139","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}